The expression of CMTM6 in ICs was also detected in CRC patients treated with immunotherapy, and CMTM6 was mainly expressed in CD68+ macrophages (46.9%, 15/32) and to a lesser degree in CD4+ T lymphocytes (21.9%, 7/32), CD8+ T lymphocytes (21.9%, 7/32) and CD163+ M2 macrophages (18.8%, 6/32, Table 2). The gene discussed is CD163; the disease is colorectal carcinoma.